# US 2019/0375723 A1 · New Naphtho[2,3-B]Furan Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375723 A1
- Document ID: US20190375723A1
- Status: Published application
- Kind: A1
- Application number: 16/463,162
- Filed: 2017-11-22
- Published: 2019-12-12
- Earliest claimed: 2016-11-22
- Assignees: Boston Biomedical, Inc.
- Applicants: Boston Biomedical, Inc.
- Inventors: Hitoshi Ban; Seiji Kamioka; Manabu Kusagi
- Web page: https://patentgrep.com/patent/US20190375723A1

## CPC

- C07D 307/92: Naphthofurans; Hydrogenated naphthofurans
- A61P 35/00: Antineoplastic agents
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a compound useful as a novel antitumor agent targeting a CSC that is important in continuous proliferation of malignant tumor, metastasis and recurrence of cancer, and its resistance to an antitumor agent; a medicament comprising the compound as an active ingredient; a pharmaceutical composition; and an antitumor agent; as well as a method of treating cancer and/or a method of preventing cancer. The present invention provides compounds represented by formula (I): or pharmaceutically acceptable salts thereof, wherein X is an oxygen atom or sulfur atom; R1 is a hydrogen atom, an alkyl group, or the like; R2 is a halogen atom or the like; R3 is a hydrogen atom, an alkyl group, or the like; m is 0, 1, 2, 3, or 4; and n is 1, 2, 3, or 4 (with the proviso that the sum of m and n is 1, 2, 3, or 4).

## Claims

### Claim 1

A compound represented by formula (I):
or a pharmaceutically acceptable salt thereof, wherein
X is an oxygen atom or sulfur atom;
R1 is a hydrogen atom, a cyano group, a trifluoromethyl group, a trifluoromethoxy group, an optionally substituted C1-6alkyl group, an optionally substituted C2-6alkenyl group, an optionally substituted C2-6alkynyl group, an optionally substituted C3-10cycloalkyl group, an optionally substituted C3-10cycloalkenyl group, an optionally substituted 3 to 10-membered saturated heterocyclic group, an optionally substituted C6-10aryl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, —OR4, or —SR4;
each R2 is independently a halogen atom, a cyano group, a nitro group, a trifluoromethyl group, a trifluoromethoxy group, an optionally substituted C1-6alkyl group, an optionally substituted C2-6alkenyl group, an optionally substituted C2-6alkynyl group, an optionally substituted C3-10cycloalkyl group, an optionally substituted C3-10cycloalkenyl group, an optionally substituted C1-6alkylcarbonyl group, an optionally substituted C3-10cycloalkylcarbonyl group, an optionally substituted C6-10arylcarbonyl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroarylcarbonyl group, an optionally substituted 3 to 10-membered saturated heterocyclic group, an optionally substituted C6-10aryl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C1-6alkylsulfonyl group, an optionally substituted C3-10cycloalkylsulfonyl group, an optionally substituted C6-10arylsulfonyl group, an optionally substituted aminosulfonyl group, —N(R′)2, or —SR4;
each R3 is independently a hydrogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C2-6alkenyl group, an optionally substituted C2-6alkynyl group, an optionally substituted C3-10cycloalkyl group, an optionally substituted C3-10cycloalkenyl group, an optionally substituted 3 to 10-membered saturated heterocyclic group, an optionally substituted C6-10aryl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C1-6alkylcarbonyl group, an optionally substituted C3-10cycloalkylcarbonyl group, an optionally substituted C6-10arylcarbonyl group, an optionally substituted 3 to 10-membered saturated heterocyclylcarbonyl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroarylcarbonyl group, an optionally substituted C1-6alkyloxycarbonyl group, an optionally substituted C3-10cycloalkyloxycarbonyl group, an optionally substituted C6-10aryloxycarbonyl group, an optionally substituted 3 to 10-membered saturated heterocyclyloxycarbonyl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryloxycarbonyl group, an optionally substituted C1-6alkylaminocarbonyl group, an optionally substituted C3-10cycloalkylaminocarbonyl group, an optionally substituted C6-10arylaminocarbonyl group, an optionally substituted 3 to 10-membered saturated heterocyclylaminocarbonyl group, or an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroarylaminocarbonyl group;
m is O, 1, 2, 3, or 4 and n is 1, 2, 3, or 4, with the proviso that the sum of m and n is 1, 2, 3, or 4; and
each R4 is independently a hydrogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C2-6alkenyl group, an optionally substituted C2-6alkynyl group, an optionally substituted C3-10cycloalkyl group, an optionally substituted C3-10cycloalkenyl group, an optionally substituted 3 to 10-membered saturated heterocyclic group, an optionally substituted C6-10aryl group, or an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, or when two R4 are attached to a nitrogen atom, the two R4 may be taken together with the nitrogen atom to which they are attached to form a nitrogen-containing 3 to 10-membered saturated heterocyclic group,
with the proviso that the following compounds are excluded:
5-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-carbaldehyde;
2-acetyl-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-8-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-8-methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-8-hydroxy-7-methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6,7-di methoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7,8-dimethoxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5,6-dimethoxynaphtho[2,3-b]furan-4,9-dione;
2-benzoyl-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carbaldehyde;
5-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carbaldehyde;
8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carbaldehyde;
8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylic acid;
2-acetyl-8-hydroxynaphtho[2,3-b]thiophene-4,9-dione;
2-acetyl-5-hydroxynaphtho[2,3-b]thiophene-4,9-dione;
2-acetyl-5,8-dihydroxynaphtho[2,3-b]thiophene-4,9-dione;
8-hydroxy-2-propanoylnaphtho[2,3-b]thiophene-4,9-dione;
2-acetyl-8-methoxynaphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylic acid;
methyl 8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
methyl 5-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
8-hydroxy-2-(2-methylpropanoyl)naphtho[2,3-b]thiophene-4,9-dione;
2-acetyl-8-hydroxy-7-(hydroxymethyl)naphtho[2,3-b]thiophene-4,9-dione;
2-acetyl-5,8-dimethoxynaphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-propanoylnaphtho[2,3-b]thiophene-4,9-dione;
ethyl 8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
8-hydroxy-2-(thiophene-2-ylcarbonyl)naphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-(2-methylpropanoyl)naphtho[2,3-b]thiophene-4,9-dione;
2-benzoyl-5-hydroxynaphtho[2,3-b]thiophene-4,9-dione;
2-benzoyl-8-hydroxynaphtho[2,3-b]thiophene-4,9-dione;
propan-2-yl 8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
ethyl 8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
8-methoxy-2-(thiophene-2-ylcarbonyl)naphtho[2,3-b]thiophene-4,9-dione;
propan-2-yl 8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
2-benzoyl-8-methoxynaphtho[2,3-b]thiophene 4,9-dione;
8-hydroxy-2-(phenylacetyl)naphtho[2,3-b]thiophene-4,9-dione;
8-hydroxy-2-(4-methoxybenzoyl)naphtho[2,3-b]thiophene-4,9-dione;
2-(4-chlorobenzoyl)-8-hydroxynaphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-(4-methoxybenzoyl)naphtho[2,3-b]thiophene-4,9-dione;
8-hydroxy-2-(3-phenylpropanoyl)naphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-(phenylacetyl)naphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-(3-phenylpropanoyl)naphtho[2,3-b]thiophene-4,9-dione;
8-hydroxy-2-(phenoxyacetyl)naphtho[2,3-b]thiophene-4,9-dione;
8-hydroxy-2-(pyridin-3-ylcarbonyl)naphtho[2,3-b]thiophene-4,9-dione;
2-(4-chlorobenzoyl)-8-methoxynaphtho[2,3-b]thiophene-4,9-dione;
4-methoxybenzyl 8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
2-phenylethyl 8-hydroxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
8-methoxy-2-(phenoxyacetyl)naphtho[2,3-b]thiophene-4,9-dione;
8-methoxy-2-(pyridin-3-ylcarbonyl)naphtho[2,3-b]thiophene-4,9-dione;
4-methoxybenzyl 8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate;
8-hydroxy-2-(2-hydroxy-4-methoxybenzoyl)naphtho[2,3-b]thiophene-4,9-dione;
2-phenylethyl 8-methoxy-4,9-dioxo-4,9-dihydronaphtho[2,3-b]thiophene-2-carboxylate; and
2-(2-hydroxy-4-methoxybenzoyl)-8-methoxynaphtho[2,3-b]thiophene-4,9-dione.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is an oxygen atom.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is a C1-6alkyl group optionally substituted with one to three halogen atoms, hydroxyl groups, one or two C1-6alkyloxy groups, or a 3 to 10-membered saturated heterocyclic group.

### Claim 4 (depends on 3)

The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R1 is a methyl group.

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently a halogen atom, a cyano group, an optionally substituted C1-6alkyl group, an optionally substituted C2-6alkenyl group, an optionally substituted C2-6alkynyl group, an optionally substituted C3-10cycloalkenyl group, an optionally substituted C1-6alkylcarbonyl group, an optionally substituted C6-10aryl group, or an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group.

### Claim 6 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently a halogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C6-10aryl group, or an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group.

### Claim 7 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently a halogen atom or an optionally substituted C1-6alkyl group.

### Claim 8 (depends on 5)

The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein each R2 is independently a halogen atom.

### Claim 9 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each R3 is independently a hydrogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C6-10aryl group, an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C1-6alkylcarbonyl group, an optionally substituted C6-10arylcarbonyl group, an optionally substituted C1-6alkyloxycarbonyl group, an optionally substituted C1-6aryloxycarbonyl group, an optionally substituted C1-6alkylaminocarbonyl group, or an optionally substituted C6-10arylaminocarbonyl group.

### Claim 10 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein each R3 is independently a hydrogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C6-10arylcarbonyl group, or an optionally substituted C1-6alkyloxycarbonyl group.

### Claim 11 (depends on 9)

The compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein each R3 is independently a hydrogen atom.

### Claim 12 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently a hydrogen atom, an optionally substituted C1-6alkyl group, an optionally substituted C3-10cycloalkyl group, an optionally substituted C6-10aryl group, or an optionally substituted 5 to 12-membered monocyclic or polycyclic heteroaryl group, or when two R4 are attached to a nitrogen atom, the two R4 may be taken together with the nitrogen atom to which they are attached to form a nitrogen-containing 3 to 10-membered saturated heterocyclic group.

### Claim 13 (depends on 12)

The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein each R4 is independently a hydrogen atom or an optionally substituted C1-6alkyl group, or when two R4 are attached to a nitrogen atom, the two R4 may be taken together with the nitrogen atom to which they are attached to form a nitrogen-containing 3 to 10-membered saturated heterocyclic group.

### Claim 14 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein m and n are both 1.

### Claim 15 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is a methyl group; each R2 is independently a halogen atom or an optionally substituted C1-6alkyl group; and each R3 is independently a hydrogen atom.

### Claim 16 (depends on 15)

The compound according to claim 15, or a pharmaceutically acceptable salt thereof, wherein m and n are both 1.

### Claim 17 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is a methyl group; each R2 is independently a halogen atom; and each R3 is independently a hydrogen atom.

### Claim 18 (depends on 17)

The compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein m and n are both 1.

### Claim 19 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of the following compounds:
2-acetoxy-8-chloro-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-bromo-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7-bromo-8-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-butyl-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-hydroxy-6-(4-methoxyphenyl)naphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-hydroxy-6-(2-methoxypyrimidin-5-yl)naphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-bromo-5-(methoxymethoxy)naphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-bromo-4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-5-yl benzoate;
2-acetyl-6-bromo-4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-5-yl 2-methyl propyl carbonate;
2-acetyl-6-chloro-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7-chloro-5-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-chloro-8-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-chloro-8-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7-chloro-8-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-8-chloro-7-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-6-chloro-7-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-chloro-7-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-5-chloro-6-hydroxynaphtho[2,3-b]furan-4,9-dione;
2-acetyl-7-chloro-6-hydroxynaphtho[2,3-b]furan-4,9-dione; and
2-acetyl-8-chloro-6-hydroxynaphtho[2,3-b]furan-4,9-dione.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

An anticancer agent comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 22 (depends on 21)

The anticancer agent according to claim 21, wherein the cancer is at least one cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant lymphoma, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small-cell lung cancer, breast cancer, gastric cancer, gallbladder⋅bile duct cancer, hepatoma, pancreatic cancer, colon cancer, rectal cancer, chorioepithelioma, chorioblastoma, choriocarcinoma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, testicular tumor, Wilms' tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, and soft tissue sarcoma.

### Claim 23 (depends on 1)

A method for treating a cancer, characterized by administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to a patient in need of the treatment.

### Claim 24 (depends on 23)

The method for treating according to claim 23, wherein the cancer is at least one cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant lymphoma, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small-cell lung cancer, breast cancer, gastric cancer, gallbladder⋅bile duct cancer, hepatoma, pancreatic cancer, colon cancer, rectal cancer, chorioepithelioma, chorioblastoma, choriocarcinoma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, testicular tumor, Wilms' tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, and soft tissue sarcoma.

### Claim 25 (depends on 1)

The use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic agent for cancer.

### Claim 26 (depends on 25)

The use of a compound according to claim 25 or a pharmaceutically acceptable salt thereof, wherein the cancer is at least one cancer selected from the group consisting of acute leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, polycythemia vera, malignant lymphoma, brain tumor, head and neck cancer, esophageal cancer, thyroid cancer, small cell lung cancer, non-small-cell lung cancer, breast cancer, gastric cancer, gallbladder⋅bile duct cancer, hepatoma, pancreatic cancer, colon cancer, rectal cancer, chorioepithelioma, chorioblastoma, choriocarcinoma, endometrial cancer, cervical cancer, urothelial cancer, renal cell cancer, testicular tumor, Wilms' tumor, skin cancer, malignant melanoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, and soft tissue sarcoma.
